NCT06126276 2026-03-18
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Mayo Clinic
Fred Hutchinson Cancer Center
Emory University
M.D. Anderson Cancer Center
National Guard Health Affairs
Rigshospitalet, Denmark
Seoul National University Bundang Hospital